Recent studies suggest that the prevalence of vitamin D deficiency is continuously increasing worldwide. 3, 4 It is estimated that more than 1 billion people of all ages worldwide have serum (NHANES III 1988-1994 to 36% and 41% (NHANES 2001(NHANES -2004 Generally major determinants of vitamin D status are latitude, seasonality, skin pigmentation, clothing and use of sunscreens, and also supplement use and eating vitamin D fortified foods. In Poland sunlight exposure is the primary determinant of vitamin D status 5,11 because there are no vitamin D fortified foods. Recommendation of vitamin D supplementation 2 are not probably properly implemented in Poland. There is also no recommendation for supplementation.
Introduction
Understanding of vitamin D role in optimal health has expanded greatly in the past few years. Grant indicated 1 that increasing western Europeans' serum 25(OH)D levels to at least 100 nmol/L all year could significantly reduce rates and economic burdens of several types of diseases whereas the reduction in healthcare expenditures was estimated to be 187,000 million Euro per year. The most important benefits would come for cancer, cardiovascular disease, diabetes mellitus, respiratory infections, dental/ periodontal diseases and other. For these reasons the Polish consensus on vitamin D supplementation and standards were published on the beginning of 2010 2 and implemented into practice. However, data concerning epidemiology of vitamin D deficiency in Poland is still alarming. High prevalence of vitamin D deficiency has other economic burdens. It negatively affects effectiveness of expensive pharmacotherapies in infectious diseases (chronic hepatitis C, tuberculosis), osteoporosis, multiple sclerosis, epilepsy, Chronic Kidney Diseases and atopic dermatitis. 
Effect of Vitamin D Status on Pharmacological Treatment Efficacy
Recent evidence suggests that vitamin D may impact on clinical outcomes and treatment response in some diseases. Therapeutic effects of vitamin D as adjunctive therapy to basic therapies were investigated. Vitamin D supplementation and infectious diseases. The current body of evidence supports the view that vitamin D supplementation holds promises as risk-modifying intervention in tuberculosis (TB), influenza and viral upper respiratory illnesses. [17] [18] [19] [20] [21] [22] [23] [24] There has been a particular interest on the possible role of vitamin D supplementation as adjunctive therapy in settings of infection. A clear benefit of adjunctive vitamin D therapy in TB treatment, chronic hepatitis C (CHC) infection and acute lower respiratory infections (ALRI) was observed. [17] [18] [19] [20] [21] [22] [23] [24] Interferon (IFN)-based treatment for hepatitis C virus (HCV) infection has a therapeutic limitation and side effects, a more efficient therapeutic strategy is desired. Two small prospective randomized controlled studies showed that those patients who received vitamin D 3 supplementation of 2000 IU/day, targeting a 25(OH)D level > 80 nmol/L, in addition to PEG-IFN/ RBV combination therapy, had higher rates of rapid virologic response (RVR; 44% vs. 17%, p < 0.001), complete early virologic response (cEVR; 94% vs. 48%, p < 0.001) and sustained virological response SVR (86% vs. 42%; OR 2.5, 95% CI 2.0-4.9, p < 0.001) in HCV-1 [36] and SVR (95% vs. 77%, p < 0.001) in HCV-2/3 infection compared with subjects treated with standard therapy. Moreover, recipients of vitamin D3 supplementation were less likely to relapse or non-respond to antiviral therapy. Similarly, a small retrospective study showed vitamin D 3 supplementation improved SVR rate in the treatment of recurrent hepatitis C post liver transplantation (53.3% vs. 18.5%, p = 0.02). [17] [18] [19] Leis 24 documented that in children < 5 y old whose vitamin D intake was less than 80 IU/kg/d were greater than 4 times The definition of non-response to bisphosphonate therapy was based on the EUROFORS study, which identified patients for teriparatide therapy after "failing" anti-resorptive agents (median duration of bisphosphonate treatment was 36 mo). Non-response included any of the following: (1) T-score of < −3.0 at the lumbar spine, femoral neck, total hip, or trochanter despite > 24 mo of bisphosphonates therapy; (2) These data are supported by work of Hokugo 35 who described increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. Necrotic bone in the oral cavity has recently been reported in patients treated with nitrogen-containing bisphosphonates as part of their therapeutic regimen for multiple myeloma or metastatic cancers to bone. Similar to human patients, rat ONJ lesions prolonged the oral exposure of necrotic bone sequestra and were uniquely associated with pseudoepitheliomatous hyperplasia. It was suggested that the pathophysiologic mechanism(s) underpinning ONJ may involve the interaction between bisphosphonates and compromised vitamin D functions in the realm of skeletal homeostasis and innate immunity.
The important part of osteoporosis therapy is rehabilitation after fracture. Bischoff-Ferrari 36 evaluated the effect of 800-2000 IU daily cholecalciferol and extended physiotherapy (PT) on complications after hip fracture. At baseline, 50.9% of participants had 25(OH)D levels of less than 12 ng/mL and 97.7% of less than 30 ng/mL. Extended PT was successful in reducing falls but not hospital readmissions, whereas cholecalciferol treatment, 2000 IU/d, was successful in reducing hospital readmission but not falls. Thus, the two strategies may be useful together because they address two different and important complications after hip fracture. Vitamin D supplementation as adjunctive therapy in neurological disorders. Khoraminya 39 reported therapeutic effects of vitamin D 3 (1500 IU/day) as adjunctive therapy to fluoxetine (20mg) in 42 patients with major depressive disorder. In the 8-week, doubleblind, randomized, placebo-controlled trial depression severity based on Hamilton Depression Rating Scale HDRS and Beck Depression Inventory BDI decreased significantly after intervention, with a significant difference between the two groupsthe vitamin D + fluoxetine combination was significantly better than fluoxetine alone from the 4th week of treatment.
The exact mechanism by which vitamin D exerts its beneficial effect in epilepsy is still to be explored. Vitamin D receptors as well as the 1a-hydroxylase, the enzyme that produces 1,25(OH) 2 D, are distributed widely in the brain. 40 Vitamin D deficiency is known to be highly prevalent among epilepsy patients, but only one study, published nearly 40 y ago, documented that administration of vitamin D2 resulted in a seizure reduction of 30% on average. 41 In small study of Hollo 
Conclusions
There is a substantial and growing body of evidence indicating that the lower end of the adequate range is at least 80 nmol/L and, by some criteria, 100 nmol/L. 
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